GlobeNewswire

PaperCut Releases Version 18.0 with Print Room, Fab Lab Capabilities

Dela

Education, professional service and commercial customers now able to manage specialty production and 3D printing capabilities under one easy-to-use solution

MELBOURNE, Australia, Feb. 14, 2018 (GLOBE NEWSWIRE) -- PaperCut, a global software company, today announced the general availability of its PaperCut MF v18.0  software, bringing specialty production printing and 3D printing under one, easy to use software solution. Admins and operators can simply manage all specialty jobs, while also taking advantage of PaperCut's powerful cost management, security and user identification features with the new Job Ticketing capability.

The update connects in-house print rooms and fab labs at educational institutions, legal organizations, local governments, commercial organizations and hospitals to PaperCut's print management system. The Job Ticketing capability allows operators to accept specialty and 3D printing job submissions, such as laser cutting and prototype production, and track them through the production process while communicating the status to the requesting user.

"Until now, the lack of connection between our customers' general and specialty printing solutions - such as print rooms and 3D fab labs - has been a burden that cost them both time and money," said Chris Dance, co-founder and CEO of PaperCut. "To solve these problems, we've created a simple solution that will improve their specialty printing controls, security and payment options."

Because this feature falls under the same software individuals use to manage general office printing, users don't have to set up a separate profile or be re-authenticated to submit a print request, track its progression and flag questions or last-minute changes to the operator. This allows operators to spend less time managing processes-which are often manual and time-consuming-and more time driving adoption of their services and delivering high quality products for their customers.

Previously, organizations needing specialty prints lack affordable or efficient options-or both-to produce and manage jobs. Businesses would either have to use tedious, manual approaches to tracking and management, or purchase expensive software solutions limited in scope.

"The need for specialty print production is only increasing for organizations, especially universities," said Andy Slawetsky, President of Industry Analysts, Inc. "This market barely existed five years ago. Since then, there's been a rapid increase in demand resulting in a high unmet need for specialty print jobs to be managed and tracked under a unified capacity."

In addition to increased integration and workflow efficiency, the v18.0 release:

  • Reduces the need to purchase additional software packages for the print room
  • Supports all document formats and fonts on customers' personal, work and mobile devices.
  • Leverages customers' existing user permissions and accounting environment, charging for a job at any point straight back to their account.
  • Enables end users to submit a print room or 3D job through the streamlined web interface.
  • Builds a "personal touch" into the technology print room customers love, allowing for direct operator-customer communication and consistent updates on order progress.

Following PaperCut's true vendor-neutral approach, PaperCut MF v18.0 additional embedded solutions and updates have been made across a breadth of MFD devices, ensuring the platform stays up and running in conjunction with manufacturer progress. For full details on interoperability and product specs, please review the release notes, accessible here.

Availability

PaperCut MF v18.0 is now available to existing and future customers and partners. Pricing is licensed per print room as one standard product, with education and commercial customers having access to a single price exclusively as a feature of PaperCut.

About PaperCut Software
Around the world, workplaces are wrestling with printing costs and print management complexity. PaperCut is solving those problems, one workplace at a time. Since 1998, PaperCut has helped 50 million users in 175 countries save trillions of pages of paper. With PaperCut in their print environment, IT managers solve their nagging print problems once and for all. How? Its two software solutions - PaperCut MF and PaperCut NG - are cross-platform and vendor neutral. That means they work with any printer and any operating system. Plus, both solutions feature ground-breaking technology such as mobility print, secure print release, and rich reporting tools. Businesses of all shapes, sizes and industry benefit from the control, security and financial and environmental savings that PaperCut software was built for. Learn more at www.papercut.com.

Media Contact
Morgann Dulle
10Fold Communications for PaperCut
papercut@10fold.com
+1 (479) 586-1377




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Papercut Services North America LLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum